Cellino Biotech, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, focused on developing autologous induced pluripotent stem cell (iPSC)-derived cell therapies for degenerative diseases. The company's lead program targets Parkinson's disease using patient-derived dopamine neurons[@cellino].
Founded in 2017, Cellino's platform enables the manufacture of personalized cell therapies that avoid immune rejection. The company combines advances in stem cell biology with proprietary manufacturing technologies to create scalable cell replacement therapies[@ipsc2020].
Pipeline Overview
| Program | Cell Type | Indication | Phase | Status | |---------|-----------|------------|-------|--------| | CLNO-001 | Autologous iPSC dopamine neurons | Parkinson's Disease | Preclinical | Research | | Program 2 | iPSC-derived cells | CNS disorder | Discovery | Research | | Program 3 | iPSC-derived cells | Degenerative disease | Discovery | Research |
Parkinson's Disease Program
CLNO-001
CLNO-001 is an autologous iPSC-derived dopamine neuron therapy for Parkinson's disease. The therapy uses the patient's own cells to replace the dopaminergic neurons lost in PD[@cell2022].
Mechanism of Action:
Patient-derived iPSCs
Differentiation to dopamine neurons
Surgical implantation to striatum
Integration and function
Approach: ...
Cellino Biotech
Overview
Cellino Biotech, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, focused on developing autologous induced pluripotent stem cell (iPSC)-derived cell therapies for degenerative diseases. The company's lead program targets Parkinson's disease using patient-derived dopamine neurons[@cellino].
Founded in 2017, Cellino's platform enables the manufacture of personalized cell therapies that avoid immune rejection. The company combines advances in stem cell biology with proprietary manufacturing technologies to create scalable cell replacement therapies[@ipsc2020].
Pipeline Overview
| Program | Cell Type | Indication | Phase | Status | |---------|-----------|------------|-------|--------| | CLNO-001 | Autologous iPSC dopamine neurons | Parkinson's Disease | Preclinical | Research | | Program 2 | iPSC-derived cells | CNS disorder | Discovery | Research | | Program 3 | iPSC-derived cells | Degenerative disease | Discovery | Research |
Parkinson's Disease Program
CLNO-001
CLNO-001 is an autologous iPSC-derived dopamine neuron therapy for Parkinson's disease. The therapy uses the patient's own cells to replace the dopaminergic neurons lost in PD[@cell2022].
Mechanism of Action:
Patient-derived iPSCs
Differentiation to dopamine neurons
Surgical implantation to striatum
Integration and function
Approach:
| Step | Description | |------|-------------| | Cell collection | Patient blood/skin sample | | iPSC generation | Reprogramming to pluripotent state | | Differentiation | Directed to dopamine neurons | | Quality control | Purity, potency, safety | | Implantation | Stereotactic surgery |
Advantages:
Autologous (no immune rejection)
Patient-specific
Unlimited cell source
Potential for cure
Development Status:
Preclinical development
IND-enabling studies planned
Manufacturing scale-up
Technology Platform
iPSC Platform
Cellino has developed a comprehensive iPSC platform: